Nanomol Technologies has been present in Catalan media (Televisió de Catalunya TV3 and La Vanguardia) with the announcement that together with The Center of Genetic Engineering and Biotecnology (CIGB-Biocubafarma) and Heber Biotec it has started to clinically validate a new drug that aims at improving the healing of diabetic foot ulcers and preventing amputation. More information at: http://www.ccma.cat/tv3/alacarta/valor-afegit/fer-negocis-despres-de-fidel/video/5636552/ http://www.ccma.cat/tv3/alacarta/telenoticies-migdia/telenoticies-migdia-07122016/video/5636311/ http://icmab.es/images/attachments/2016/Reportatge_NANOMOL_TECH_La_Vanguardia_18_12_2016_CAT.pdf
The Naturejobs newsletter has published an article focusing in the high-quality science of Catalonia, a semiautonomous region in the far northeast of Spain. This special issue has shown by graphics and numbers the excellent scientific situation in this bioregion. Furthermore, it has highlighted all the scientific opportunities and careers that are taking place in the present. In this issue, Nanomol Technologies describes DELOS manufacturing procedure and QUATSUVs...
A review article titled “Lipid-based nanovesicles for nanomedicine” was published online in Chemical Society Reviews (2015 impact factor: 34.09). The article, authored by researchers from Institut de Ciència de Materials de Barcelona (ICMAB-CSIC), Nanomol Technologies SA and Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), summarized the research progress regarding lipid-based nanovesicles (L-NVs), focusing on the new generation of non-liposomal L-NVs. Since the overspread...
Nanomol is proud to introduce its new website. Our new website includes detailed information on our services and technologies, including Quatsuv and Delos technologies and Particle Characterization services.